Every drug sponsor wants to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. That’s always something of a moving target, especially in a field as new as AI. The Pink Sheet’s globe-spanning coverage has produced one rule of thumb, however: The closer AI is to patient care, the more scrutiny it will get. Regulators seem content to allow firms to make product development decisions based on AI without significant oversight.

Download a sample of our coverage from Asia, Europe, and the United States of the emerging framework for artificial intelligence regulation.